¼¼°èÀÇ ºñ¾ËÄڿüº Áö¹æ°£¿°(NASH) ½ÃÀå º¸°í¼­(2025³â)
Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2025
»óǰÄÚµå : 1815659
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,362,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,196,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,031,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ºñ¾ËÄڿüº Áö¹æ°£¿°(NASH) ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ºñ¾àÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. 2029³â¿¡ CAGRÀº 32.3%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµÇ°í 185¾ï 5,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº NASH ÀǾàǰ °³¹ß ÁøÀü, NASH °ËÁø È®´ë, ÀÇ·áºñ ÁöÃâ Áõ°¡, °øµ¿ ¿¬±¸ ³ë·Â, Á¤ºÎ Áö¿ø ¹× ±ÔÁ¦ °­È­ µî¿¡ ±âÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â »ýȰ½À°ü °³¼± ¹× ȯÀÚ ±³À°¿¡ ÁÖ·ÂÇÏ´Â °æÇâ, ÀÓ»ó ¿¬±¸ Çù·Â È®´ë, ±ÔÁ¦ ¹ßÀü ¹× °æ·Î ÁöÁ¤, Áø´Ü ¹× ¸ð´ÏÅ͸µ¿¡ ÀΰøÁö´É(AI) ÅëÇÕ µîÀÌ Æ÷ÇԵ˴ϴÙ.

ÇâÈÄ 5³â°£ 32.3% ¼ºÀåÀ̶ó´Â Àü¸ÁÄ¡´Â ÇØ´ç ½ÃÀå¿¡ ´ëÇÑ ÀÌÀü ÃßÁ¤Ä¡ ´ëºñ 0.5% ¼ÒÆø ÇÏÇâ Á¶Á¤µÈ ¼öÄ¡ÀÔ´Ï´Ù. ÀÌ ÇÏÇâ Á¶Á¤Àº ÁÖ·Î ¹Ì±¹°ú Ÿ±¹ °£ °ü¼¼ ¿µÇâ ¶§¹®ÀÔ´Ï´Ù. °ü¼¼ ÀλóÀ¸·Î ½ºÀ§½º ¹× ÀϺ»»ê ÆÄ³×¼ÒÀ̵å X ¼ö¿ëü ÀÛ¿ëÁ¦(FXR agonists)¿Í ¼¼Æ÷»ç¸ê ½ÅÈ£ Á¶Àý Ű³ªÁ¦ 1 ¾ïÁ¦Á¦(ASK-1 inhibitors)ÀÇ ºñ¿ëÀÌ Áõ°¡ÇÏ¿© ¹Ì±¹ °£Áúȯ Ŭ¸®´Ð¿¡ ºÎ´ãÀÌ µÉ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ¼¶À¯Áõ Ä¡·á Áö¿¬ ¹× ´ë»ç¼º °£Áúȯ °ü¸® ºñ¿ë Áõ°¡·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ »óÈ£ °ü¼¼ ºÎ°ú¿Í ¹«¿ª ±äÀå ¹× Á¦ÇÑ °­È­·Î ÀÎÇÑ Àü ¼¼°è °æÁ¦ ¹× ¹«¿ª¿¡ ´ëÇÑ ºÎÁ¤Àû ¿µÇâÀ¸·Î ±× ¿µÇâÀÌ ´õ¿í ±¤¹üÀ§ÇÏ°Ô ³ªÅ¸³¯ °ÍÀÔ´Ï´Ù.

ºñ¸¸ À¯º´·ü Áõ°¡°¡ ºñ¾ËÄڿüº Áö¹æ°£¿°(NASH) ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ºñ¸¸Àº ƯÁ¤ ½ÅÀå¿¡ ºñÇØ °Ç°­ÇÑ Ã¼ÁßÀ» ÃʰúÇÏ´Â °ÍÀº ¹°·Ð, »ó´çÇÑ °Ç°­ À§ÇèÀ» ÃÊ·¡ÇÏ´Â ºñÁ¤»óÀûÀ̰ųª °úµµÇÑ Áö¹æ ÃàÀûÀÌ Æ¯Â¡ÀÔ´Ï´Ù. ºñ¸¸ À¯Çà°ú ¿¬°èµÈ ºñ¾ËÄڿüº Áö¹æ°£ ÁúȯÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó, NASH´Â ÇâÈÄ ¼ö½Ê ³â µ¿¾È ÁßÁõ °£ ÁúȯÀÇ ÁÖ¿ä ¿øÀÎ Áß Çϳª·Î ºÎ»óÇÒ °ÍÀ¸·Î ¿¹»óµÇ¾î NASH Ä¡·á ¹× °ü·Ã ¾à¹°¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁú °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 3¿ù ¿µ±¹¿¡ º»ºÎ¸¦ µÐ ±¹Á¦ °øÁߺ¸°Ç±â±¸ÀÎ ¼¼°èº¸°Ç±â±¸(WHO)´Â 2022³â ±âÁØ 18¼¼ ÀÌ»ó ¼ºÀÎ ¾à 25¾ï ¸íÀÌ °úüÁßÀ¸·Î ºÐ·ùµÇ¾úÀ¸¸ç, ÀÌ Áß 8¾ï 9,000¸¸ ¸íÀÌ ºñ¸¸ »óŶó°í º¸°íÇß½À´Ï´Ù. µû¶ó¼­ ºñ¸¸ »ç·ÊÀÇ Áõ°¡´Â ºñ¾ËÄڿüº Áö¹æ°£¿°(NASH) ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°, ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Non-alcoholic steatohepatitis (NASH) represents an advanced stage of fatty liver disease, distinguished by inflammation of the liver, and has the potential to progress to cirrhosis and liver failure.

Non-alcoholic steatohepatitis (NASH) is classified into solid and liquid forms. Solid variants are predominantly produced in crystalline forms, sold in tablet formats for oral consumption, owing to their superior purity and durability. Products in this category, such as vitamin E, pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, and others, target various health conditions including hypertension, heart disease, high blood lipid, type 2 diabetes, and obesity. These products are distributed through hospital pharmacies, retail pharmacies, and online providers, encompassing both oral and parenteral applications.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The non-alcoholic steatohepatitis (NASH) market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis (NASH) market statistics, including non-alcoholic steatohepatitis (NASH) industry global market size, regional shares, competitors with non-alcoholic steatohepatitis (NASH) market share, detailed non-alcoholic steatohepatitis (NASH) market segments, market trends, and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis (NASH) industry. This non-alcoholic steatohepatitis (NASH) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The non-alcoholic steatohepatitis (NASH) market size has grown exponentially in recent years. It will grow from $4.5 billion in 2024 to $6.06 billion in 2025 at a compound annual growth rate (CAGR) of 34.7%. The growth in the historic period can be attributed to rising prevalence of NASH, obesity epidemic, growing awareness and diagnoses, shift in lifestyle and dietary patterns, healthcare infrastructure development.

The non-alcoholic steatohepatitis (NASH) market size is expected to see exponential growth in the next few years. It will grow to $18.55 billion in 2029 at a compound annual growth rate (CAGR) of 32.3%. The growth in the forecast period can be attributed to advancements in NASH drug development, increasing NASH screening initiatives, rising healthcare expenditure, collaborative research efforts, government support and regulations. Major trends in the forecast period include focus on lifestyle interventions and patient education, increased collaboration in clinical research, regulatory advancements and pathway designations, integration of artificial intelligence in diagnosis and monitoring.

The forecast of 32.3% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations may burden U.S. hepatology clinics by increasing costs of farnesoid x receptor agonists and apoptosis signal-regulating kinase 1 inhibitors sourced from Switzerland and Japan, potentially delaying fibrosis treatment and raising metabolic liver disease management expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of obesity is driving the demand for the non-alcoholic steatohepatitis (NASH) market. Obesity is characterized by an abnormal or excessive accumulation of fat that poses significant health risks, as well as a body weight exceeding what is considered healthy for a person of a specific height. With the growing incidence of non-alcoholic fatty liver disease linked to the obesity epidemic, NASH is projected to become one of the leading causes of severe liver disease in the coming decades, heightening the demand for NASH treatments and related medications. For example, in March 2024, the World Health Organization (WHO), a UK-based international public health organization, reported that in 2022, approximately 2.5 billion adults aged 18 and older were classified as overweight, with 890 million of them living with obesity. Thus, the rise in obesity cases is expected to drive the growth of the non-alcoholic steatohepatitis (NASH) market.

The rising demographic of the geriatric population is a key driver fueling the demand for the non-alcoholic steatohepatitis (NASH) market. The geriatric population, representing individuals aged 65 and older, exhibits specific healthcare needs associated with aging. The ongoing development and advancements in treatments within the NASH market play a crucial role in enhancing overall health outcomes for the elderly, addressing a prevalent liver-related condition prevalent in aging individuals. As indicated by the World Health Organization in October 2022, the global elderly population is anticipated to witness a significant increase, with 1 in 6 individuals being 60 or older by 2030 and an estimated 2.1 billion elderly people by 2050. This demographic shift underscores the imperative role of the increasing geriatric population in driving the growth of the Non-Alcoholic Steatohepatitis (NASH) market.

Major companies in the non-alcoholic steatohepatitis (NASH) market are focusing on the development of thyroid hormone receptor-beta (THR-beta) agonists to improve liver metabolism, decrease liver fat accumulation, and enhance liver function. THR-beta agonists are compounds that specifically activate the thyroid hormone receptor-beta subtype, a crucial receptor involved in regulating metabolism, growth, and development. For instance, in March 2024, the U.S. Food and Drug Administration (FDA) approved Rezdiffra (resmetirom), the first treatment for adults with noncirrhotic NASH and moderate to advanced liver scarring (fibrosis). By selectively activating the THR-beta receptor, Rezdiffra aids in regulating lipid metabolism, resulting in a reduction of intrahepatic triglycerides and overall liver fat accumulation.

Prominent companies in the non-alcoholic steatohepatitis (NASH) market are actively engaged in the development of innovative products, exemplified by a focus on a thyroid hormone receptor (THR)-B selective agonist. This innovative therapeutic approach is designed to target fundamental underlying causes of non-alcoholic steatohepatitis. The thyroid hormone receptor, a pivotal protein regulating gene expression upon binding with thyroid hormones, plays a crucial role in various physiological processes. A case in point is Madrigal Pharmaceuticals, Inc., a US-based clinical-stage biopharmaceutical company, which completed the submission of a New Drug Application in July 2023, seeking accelerated approval for Resmetirom in the treatment of NASH with liver fibrosis. Resmetirom, offering once-daily oral therapy and liver-directed action, specifically targets hepatic steatosis, inflammation, and hepatocellular injury associated with NASH and liver fibrosis. Notably designated as a Breakthrough Therapy by the FDA, and supported by a comprehensive clinical development program, including Phase 3 trials, Resmetirom showcases significant potential to address unmet medical needs. This advancement positions it as a promising addition to the evolving treatment landscape for NASH with liver fibrosis.

In July 2022, Advanz Pharma Corp. Limited, a prominent UK-based pharmaceutical company, successfully acquired Intercept Pharmaceuticals Inc for an undisclosed sum. This strategic acquisition is designed to solidify Advanz Pharma's position in the rare disease treatment sector, specifically through the addition of the ex-U.S. rights to Ocaliva (obeticholic acid), an orphan medicine used for treating primary biliary cholangitis (PBC). Intercept Pharmaceuticals Inc., a distinguished U.S.-based biopharmaceutical company specializing in innovative therapies for progressive non-viral liver disorders, aligns well with Advanz Pharma's strategic goals in expanding its pharmaceutical portfolio.

Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-alcoholic steatohepatitis (nash) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-alcoholic steatohepatitis (NASH) market consists of sales of drugs that are used for the treatment of non-alcoholic fatty liver diseases. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-alcoholic steatohepatitis (nash) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for non-alcoholic steatohepatitis (nash) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-alcoholic steatohepatitis (nash) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Non-Alcoholic Steatohepatitis (NASH) Market Characteristics

3. Non-Alcoholic Steatohepatitis (NASH) Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis (NASH) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Non-Alcoholic Steatohepatitis (NASH) Growth Analysis And Strategic Analysis Framework

6. Non-Alcoholic Steatohepatitis (NASH) Market Segmentation

7. Non-Alcoholic Steatohepatitis (NASH) Market Regional And Country Analysis

8. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market

9. China Non-Alcoholic Steatohepatitis (NASH) Market

10. India Non-Alcoholic Steatohepatitis (NASH) Market

11. Japan Non-Alcoholic Steatohepatitis (NASH) Market

12. Australia Non-Alcoholic Steatohepatitis (NASH) Market

13. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market

14. South Korea Non-Alcoholic Steatohepatitis (NASH) Market

15. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market

16. UK Non-Alcoholic Steatohepatitis (NASH) Market

17. Germany Non-Alcoholic Steatohepatitis (NASH) Market

18. France Non-Alcoholic Steatohepatitis (NASH) Market

19. Italy Non-Alcoholic Steatohepatitis (NASH) Market

20. Spain Non-Alcoholic Steatohepatitis (NASH) Market

21. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market

22. Russia Non-Alcoholic Steatohepatitis (NASH) Market

23. North America Non-Alcoholic Steatohepatitis (NASH) Market

24. USA Non-Alcoholic Steatohepatitis (NASH) Market

25. Canada Non-Alcoholic Steatohepatitis (NASH) Market

26. South America Non-Alcoholic Steatohepatitis (NASH) Market

27. Brazil Non-Alcoholic Steatohepatitis (NASH) Market

28. Middle East Non-Alcoholic Steatohepatitis (NASH) Market

29. Africa Non-Alcoholic Steatohepatitis (NASH) Market

30. Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape And Company Profiles

31. Non-Alcoholic Steatohepatitis (NASH) Market Other Major And Innovative Companies

32. Global Non-Alcoholic Steatohepatitis (NASH) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis (NASH) Market

34. Recent Developments In The Non-Alcoholic Steatohepatitis (NASH) Market

35. Non-Alcoholic Steatohepatitis (NASH) Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â